Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression

Edited* by Webster K. Cavenee, Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA, and approved February 13, 2015 (received for review July 30, 2014)
March 3, 2015
112 (11) 3421-3426

Significance

Glioblastoma is the most common and aggressive type of glioma, with a median survival of 15 mo. A major obstacle to effective treatment is de novo or acquired resistance to standard-care therapies, including radiation and temozolomide. Enhanced DNA repair can allow damaged or mutated cells to survive, contributing to resistance and tumor recurrence. We have identified Akt3 as the dominant Akt isoform that robustly stimulates glioma progression. We also discovered key roles for Akt3 in activating DNA repair pathways, which led to enhanced survival of human glioblastoma cells following radiation or temozolomide treatment. Our work has potential broad application to multiple cancer types in which Akt3 is expressed. Blocking this pathway may help prevent or alleviate DNA repair-mediated therapeutic resistance.

Abstract

Akt is a robust oncogene that plays key roles in the development and progression of many cancers, including glioma. We evaluated the differential propensities of the Akt isoforms toward progression in the well-characterized RCAS/Ntv-a mouse model of PDGFB-driven low grade glioma. A constitutively active myristoylated form of Akt1 did not induce high-grade glioma (HGG). In stark contrast, Akt2 and Akt3 showed strong progression potential with 78% and 97% of tumors diagnosed as HGG, respectively. We further revealed that significant variations in polarity and hydropathy values among the Akt isoforms in both the pleckstrin homology domain (P domain) and regulatory domain (R domain) were critical in mediating glioma progression. Gene expression profiles from representative Akt-derived tumors indicated dominant and distinct roles for Akt3, consisting primarily of DNA repair pathways. TCGA data from human GBM closely reflected the DNA repair function, as Akt3 was significantly correlated with a 76-gene signature DNA repair panel. Consistently, compared with Akt1 and Akt2 overexpression models, Akt3-expressing human GBM cells had enhanced activation of DNA repair proteins, leading to increased DNA repair and subsequent resistance to radiation and temozolomide. Given the wide range of Akt3-amplified cancers, Akt3 may represent a key resistance factor.
Akt is among the most hyperactivated signaling pathways in human cancer and is an important kinase that regulates key cellular functions including cell growth, proliferation, angiogenesis, glucose metabolism, invasion, and survival, among others (13). Analysis of human glioblastomas (GBMs) from The Cancer Genome Atlas (TCGA) has revealed that the Akt signaling pathway is one of the top altered pathways in GBM (4, 5). Additionally, researchers have observed that the Akt activation status correlates with glioma grade (6). However, much less is known regarding the precise roles of the Akt isoforms (Akt1, Akt2, Akt3) in this disease.
Akt1, Akt2, and Akt3 share roughly 80% overall sequence identity and each contain three similar domains: a pleckstrin homology, kinase, and regulatory domain (7). Although they appear to be very similar proteins, developmental studies as well as assessment of the isoforms in cancer models have revealed that they possess distinct functions (1, 8). The most extensive work on isoform differences has been performed in breast cancer. Akt2 is reported to promote migration, invasion, and metastasis, whereas Akt1 is inhibitory (8, 9). Specific phosphorylation of palladin, an actin bundling protein, by Akt1 led to decreased migration (10). Conversely, Akt2 has been found to promote breast cancer epithelial to mesenchymal transition (EMT) through miR-200 modulation (11) as well as an interaction with Snail1 on the E-cadherin promoter (12). Functional differences in glioma have been slightly variable by using knockdown systems in transformed cells. The first studies were reported on Akt2 only, which was found to mediate invasion in rat C6 glioma cells (13), and inhibition of Akt2 prolonged survival in an orthotopic rat model (14). Subsequent reports have found that Akt2, and possibly Akt3, are important for disease progression and maintenance, whereas Akt1 does not play a major role (15, 16). Another study in transformed mouse astrocytes indicate that Akt isoform function is potentially modulated by the genetic landscape of the tumor (17). The underlying basis behind these differences and the major pathways that the isoforms use remains largely unknown. To our knowledge, our study is the first to use a glial-specific transgenic mouse model to demonstrate Akt3 as a powerful inducer of glioma progression and to further reveal the previously unidentified DNA repair function of Akt3.

Results and Discussion

Akt3 Tops Hierarchy in Mediating Glioma Progression.

To gain a broad perspective of the Akt isoforms in human cancer, we analyzed their copy number variation (CNV) across multiple cancer types. Akt3 comprised the most frequently amplified isoform in many cancers, including GBM, ovarian, melanoma, endometrial, and breast cancer (Fig. 1A). Moreover, Akt3 was the least frequently deleted isoform. In contrast, Akt1 was the least frequently amplified and most deleted isoform. These CNV data suggest that Akt3 may be the most critical isoform in an array of cancer types. Indeed, a prominent role for Akt3 has been well-documented in melanoma, playing a critical role in tumor progression (18) and rendering cells resistant to apoptosis (19). Akt3 has also been reported to be the dominant isoform in hormone unresponsive breast (20) and prostate cancer cells (21), and a recurrent MAGI3-Akt3 fusion gene was recently discovered in triple-negative breast cancer (22). Given that Akt3 represents 50% of total Akt in the normal brain, has been documented to be essential for normal brain development (23), and was preferentially amplified in GBM, we hypothesized that Akt3 is the most critical isoform involved in glioma.
Fig. 1.
Akt3 frequently amplified in cancer and tops hierarchy in glioma. (A) Copy number variation of Akt isoforms in TCGA cancers, shown in order of increasing Akt3 amplification percentage. (B) Percentage of HGG and representative tumors shown from Akt isoforms injected in conjunction with PDGFB. P values represent Fisher’s exact test. *P < 0.05, ***P < 0.001. Scale bar for images and insets, 100 and 50 µm, respectively.
We directly tested the ability of Akt1, Akt2, and Akt3 to promote glioma progression in the RCAS/Ntv-a glial-specific mouse system. As previously reported, injection of the RCAS plasmid carrying PDGFB transduces normal, nestin-positive glial cells that are engineered to express the RCAS receptor, tv-a, leading to formation of low-grade glioma (LGG) in more than 80% of mice (2426). The introduction of Akt1 in conjunction with PDGFB led to only 16% incidence of high-grade glioma (HGG), which was not statistically significant from PDGFB alone. However, when Akt2 or Akt3 was injected with PDGFB, the incidence of HGGs rose to 78% and 97%, respectively (Fig. 1B), which is significantly higher than PDGFB alone (P < 0.001, Fisher’s exact test) and Akt1 (P < 0.001, Fisher’s exact test). In addition, Akt3 produced a higher incidence of HGGs compared with Akt2 (P < 0.05, Fisher’s exact test). Akt3 tumors were particularly striking, as they frequently exhibited bilateral patterns and were very large, with pseudopalisading necrosis and marked vascular proliferation. Even the high-grade tumors differed among the Akt isoforms, with the Ki67 proliferation index again reflecting the Akt3 > Akt2 > Akt1 hierarchy (P < 0.001, Fisher’s exact test) (Fig. 1B and Fig. S1). The striking invasiveness, as evidenced by the number of bilateral tumors (Fig. S1), is consistent with a prior study that found Akt3 to promote anchorage independent growth in transformed astrocytes (17). Additionally, the cellular localization pattern of the activated form of Akt (pAkt-473) isoforms appeared to be distinct, perhaps providing clues of differential pathways being activated. Tumors derived from Akt1 displayed mostly nuclear staining of pAkt; Akt2 tumors displayed primarily membranous staining; whereas Akt3 tumors displayed strong nuclear and cytoplasmic staining (Fig. 1B). These findings are consistent with a recent phosphoproteomics screen in immortalized lung fibroblasts, which revealed more evenly distributed nuclear and cytoplasmic substrates in cells expressing Akt3, compared with those in Akt1- and Akt2-expressing cells (27). This study highlighted Akt1/3-mediated phosphorylation of an RNA processing regulator, which led to alternative splicing of FGFR2. Additional studies are reporting potential nuclear functions of Akt3, including Ago2-mediated translational repressive activities (28), transcriptional control of IGFBP3 in lung cancer cells (29), and ERBB2, ERBB3, and ERα in breast tumor cells from a mouse transgenic model (30). Although these effects are likely mediated by multiple complex systems, Akt3 has been reported to control the stability of the major nuclear export protein, chromosome maintenance region-1 (CRM-1), leading to altered mitochondrial biogenesis and autophagy (31). It is plausible that Akt3 may regulate other biological processes via similar mechanisms.

Variabilities Among Akt Isoform Domains Reflect Functional Differences.

To further explore the potential basis behind the functional differences, we compared Grantham polarity plots among the Akt isoforms, which reflect charge distribution across amino acids (32). Substantial differences were observed in two regions in the P domain (amino acids 40–55 and 120–150) and the R domain (amino acids 445–460), but the kinase domain (K domain) was the most consistent among the Akt isoforms (Fig. 2A and Dataset S1). Differences in polarity may affect protein interactions, leading to divergent cell signaling pathways. Notably, the K domain, containing one of the activating phosphorylation sites, Thr-308, had very little variation in polarity, indicating that this domain is likely not responsible for the functional differences among the isoforms. A complementary measurement of hydropathy via Kyte–Doolittle plots was consistent with the polarity plots, revealing similar variable regions (Fig. S2 and Dataset S2).
Fig. 2.
Variable regions in pleckstrin homology and regulatory domains contribute to Akt isoform function. (A) Grantham polarity values for each amino acid plotted. Enlarged portions depict variable regions. (B) Akt2/Akt1 and Akt3/Akt1 chimeras were generated by domain swapping and injected in combination with PDGFB. Representative H&E HGG images are shown. (Scale bar, 100 µm.)
We hypothesized that the variable regions in polarity and hydropathy could be responsible for the functional differences observed in glioma progression. To test this, we performed domain swapping to generate chimeras in which the P or R domains of Akt2 or Akt3 were swapped with Akt1. The resulting chimeras were referred to as 2P and 2R or 3P and 3R, respectively (Fig. 2B and Table S1). We injected each chimera with PDGFB into Ntv-a mice to determine its ability to induce progression. The data revealed that the P or the R domain of Akt2 or Akt3 strongly initiated progression. These results may have important implications for the development of future inhibitors. Prior attempts to inhibit the Akt pathway in solid tumors have involved pan Akt inhibitors, most notably perifosine, a lipid-based compound that prevents Akt translocation to the cell membrane. Phase II clinical trials with this inhibitor have not yielded favorable outcomes (33, 34). More recently, the allosteric inhibitor MK-2206, which inhibits Akt1/2 more selectively than Akt3, was evaluated in Phase I and II clinical trials, with limited single agent activity (35). Our data suggest that future attempts to inhibit Akt should specifically target Akt2 and/or Akt3.

Akt3-Specific Transcriptional Patterns Highlight DNA Damage/Repair Processes.

Given that there was a definitive hierarchy among the isoforms in promoting glioma progression, we sought to analyze the gene expression patterns of representative tumors to determine if distinct pathways were being activated. We performed microarray analysis on RNA isolated from high-grade tumors derived from PDGFB alone and each PDGFB/Akt combination. Gene expression patterns from Akt1/2/3 tumors were compared with that of PDGFB tumors. Consistent with the inability of Akt1 to induce glioma progression, there were strikingly no differentially expressed genes in Akt1 tumors compared with PDGFB. Conversely, tumors derived from Akt2 and Akt3 had 306 and 145 unique differentially expressed genes, respectively (Fig. 3A and Dataset S3). Moreover, Akt2 and Akt3 shared only 67 differentially expressed genes, indicating that they likely activate distinct pathways. To assess the specific pathways these differentially expressed genes were associated with, we performed gene ontology (GO) enrichment analysis using the WebGestalt software (36). The significantly enriched (false discovery rate < 0.05) GO categories were organized as a tree with broad/specific categories at the top and bottom. The broad categories at the top of the Akt2 tree were phosphate metabolic and protein modification processes, and the most specific category at the bottom of the tree was amino acid phosphorylation (Fig. 3B). The corresponding genes from the Akt2 tree are depicted in a heatmap, and demonstrate that indeed these genes have separate patterns from Akt1 and Akt3 (Fig. 3C). The Akt3 GO analysis was very different, with broad categories including cellular macromolecule metabolic processes, response to cellular stress, and response to DNA damage stimulus. The most specific categories were DNA-related, including DNA metabolic processes, DNA replication, and DNA repair (Fig. 3D). These results reflect the strong nuclear pattern of p-Akt staining in the mouse tumors (Fig. 1B). Many DNA repair machinery genes were significantly up-regulated, including PolD1, PolE, PolE2, EXO1, PCNA, and FEN1 (Fig. 3E). Given the striking pattern and potential implications of up-regulated DNA repair pathways, we next analyzed the human gene expression patterns in the TCGA GBM dataset to assess whether human tumors showed similar pathways that were discovered in the mouse model. Partial correlations were calculated between the expression of each Akt isoform and a panel of 356 DNA repair genes across 166 GBM samples. In accordance with the mouse expression data, Akt3 expression was significantly associated with a panel of 76 DNA repair genes (false discovery rate < 0.05 and |partial correlation| > 0.2) (Fig. 3F and Table S2). This pattern was not observed with either Akt1 or Akt2. These data highlight that the mouse model is a relevant and accurate representation of the human disease, and further, that Akt3 activation may contribute to therapeutic resistance (37).
Fig. 3.
Akt3 regulates DNA repair pathways. (A) Venn diagram representing number of shared and unique differentially expressed genes among mouse tumors generated from PDGFB with Akt1, Akt2, or Akt3. (B) GO enrichment analysis based on Akt2 differentially expressed genes. (C) Heatmap of the Akt2-related pathway genes from B. (D) GO enrichment analysis based on Akt3 differentially expressed genes. (E) Heatmap of Akt3-related pathway genes from D. (F) Partial correlation among Akt isoforms and Akt3 signature genes across 166 TCGA GBM samples.

Akt3 Enhances DNA Damage/Repair Process and Mediates Radiation and Temozolomide Resistance.

To further investigate the potential role of Akt3 in DNA damage and repair process, we generated U87 stable cell lines that overexpress Akt1, Akt2, or Akt3 (Fig. S3A). We first examined the cells for evidence of DNA damage response with γ-irradiation by assessing micronuclei (MN), a well defined readout of damaged nuclei. Strikingly, Akt3-expressing cells had the highest level of MN among them (Fig. 4A). We further characterized the role of Akt3 in DNA damage response by evaluating a key marker of DNA double strand break (DSB), p-γ-H2AX. We observed a significant increase in p-γ-H2AX foci following γ-irradiation only in Akt3 cells, compared with empty vector (Fig. 4B) (P = 0.01). We observed that overexpression of Akt3 following irradiation led to a strong phosphorylation of Ataxia telangiectasia mutated (ATM) (Fig. S3B), a major first-responder of DNA damage that mediates activation of a plethora of transducers and effectors of the DDR. It should be noted that the functional classification of 1,077 putative ATM substrates is very similar to the pathways that were enriched in Akt3-derived tumors, including chromatin organization, stress response, DNA metabolism, and responses to DNA damage (38), providing more evidence that ATM is a key player in Akt3-mediated pathways.
Fig. 4.
Specific role for Akt3 in activating DNA damage response pathways. (A, Left) Micronuclei were detected in U87 cells with Akt isoforms. (A, Right) Quantification of MN relative to control cells was assessed by counting more than 100 DAPI-stained nuclei in U87 cells with Akt isoforms exposed to 2 Gy irradiation. ***P < 0.0001 ANOVA with Dunnett’s post hoc test. (B, Left) γH2AX foci in U87 nuclei with 2 Gy irradiation, fixed and stained 30 min postirradiation. (Scale bar, 10 µm.) (B, Right) Quantification of γH2AX foci. Data represent foci in irradiated nuclei normalized to untreated nuclei. *P = 0.01, t test, corrected by multiple testing. (C) Semiquantitative PCR measuring end joining in U87 nuclear extracts. Extent of end joining assayed with primers spanning the breakpoint. (D) Homologous recombination of U87 cells stably expressing both an Akt isoform and a nonfunctional GFP cassette. Cells were transfected with I-SceI. Percent recombination represents GFP-positive cells as measured via flow cytometry. **P < 0.01, ANOVA with Dunnett’s post hoc test. (E and F) MTT measurement of U87 cell viabilty 5 d postirradiation or TMZ treatment. *P < 0.05, ***P < 0.001, two-way ANOVA with Tukey’s Post hoc test. (G) Number of mutations in TCGA GBM samples according to Akt3 copy number. P < 0.05, one tailed t test.
Next we performed experiments that directly tested the ability of Akt3 to promote nonhomologous end joining (NHEJ) and homologous recombination (HR), two major pathways for DSB repair. To assess NHEJ, we performed a cell-free assay in which linearized plasmid was incubated with nuclear extracts of U87 cells stably expressing Akt isoforms. The relative amount of religated plasmid was monitored with semiquantitative PCR. Consistent with our hypothesis, Akt3 nuclear extracts had significantly higher levels of religated plasmid, indicating Akt3 promotes NHEJ (Fig. 4C). HR was monitored using a well characterized cell-based repair system, where the Dr-GFP cassette, which contains two nonfunctional GFP genes and SceI sequences were stably transfected into U87 cells stably expressing myristoylated Akt1, Akt2, or Akt3. Upon DNA double strand break via the SceI endonuclease, cells that undergo HR produce a functional GFP allele and may be monitored via flow cytometry. The stable U87 cells were transfected with SceI and collected 48 h following transfection for flow cytometry assay. Akt3 overexpression led to a significant increase in the population of GFP cells, validating its role as a mediator of HR (Fig. 4D). These results were further corroborated in HeLa cells (Fig. S3C). Furthermore, we showed that Akt3 rendered cells resistant to irradiation and temozolomide (TMZ) treatments via cell viability assays (Fig. 4 E and F). To assess the potential level of DNA repair in human GBM, we analyzed the number of mutations according to Akt3 copy number in TCGA samples, and found that the Akt3 high group had significantly fewer mutations compared with the Akt3 low group (Fig. 4G), indicating increased DNA repair and potential therapeutic resistance. The proposed model mechanism by which Akt3 promotes DNA repair and glioma progression is depicted in Fig. S4.
GBMs are notoriously resistant to therapies and are among the most difficult cancers to treat (39). Identifying and blocking key pathways which mediate resistance could positively impact the successful treatment of this disease. We have demonstrated that Akt3 strongly promotes glioma progression and mediates activation of DNA repair pathways. We believe that this work has potential to be highly impactful, because Akt3 is operative in multiple cancer types and may be a key factor in therapeutic resistance.

Methods

Copy Number Variation Analysis.

Copy number data from various cancer types studied by TCGA were downloaded from Synapse (https://synapse.prod.sagebase.org) on March 26, 2013. Only cancer types with more than 200 samples were considered. The data were produced by the Affymetrix Genome-Wide Human SNP Array 6.0 platform (Affymetrix) and recurrent copy number changes were identified by the GISTIC software (40) as described (4). The copy number amplification and deletion thresholds were set to be 1 and −1, respectively.

Statistical Analyses of Microarray Data.

Microarray experiments were carried out using the Mouse Whole Genome Oligo Microarray kit from Agilent Technologies, following the manufacturer’s protocol (the detailed protocol can be found on the Agilent website: www.agilent.com). In brief, 500 ng of total RNA from each sample was used and labeled with Cy3- or Cy5-CTP. After 17 h of hybridization at 65 °C, the arrays were washed and scanned with Agilent’s dual-laser-based scanner. Feature extraction software GE2-v4_91 was used to link a feature to a design file and determine the relative fluorescence intensity between the samples. The raw data were analyzed using R 2.15.2 with the Limma package (3). Background correction, within- and between-array normalization were performed with parameters: bc.method = “normexp”, method = “loess”, and method = “Aquantile”, respectively. The normalized data were then log2 transformed. Selection of differentially expressed probes between conditions was carried out by the lmFit and eBayes functions included in the Limma package (41), which perform a linear model analysis and an empirical Bayes estimation of the variance, taking into account the small sample size of microarray experiments. P values were adjusted to obtain the q value, i.e., False Discovery Rate (FDR), by the Benjamini–Hochberg multiple testing correction (42). FDR is controlled at a level of 0.1. The probes were then mapped to genes (when multiple probes mapped to the same gene, the probe with the best q value was selected to represent the gene). Heatmap plots were generated using the R software package to visualize the normalized gene expression across samples. Genes were grouped by hierarchical clustering.

Functional Categories and Pathway Analysis.

Differentially expressed genes from each experimental condition were used for the pathway analysis. We performed gene ontology (GO) enrichment analyses using the WebGestalt software (36) to identify the top enriched GO categories, which were organized as Directed Acyclic Graphs (DAG, which is a tree-like structure). The most broad categories at the top of the DAG are biology process, molecular function and cellular component, respectively. Going down the DAG, the categories become more specific. The top 10 enriched categories of each tree were highlighted in red (if q value < 0.05) or maroon (otherwise).

Partial Correlation Between the Expression of Akt Isoforms and DNA Repair Genes.

DNA repair genes were downloaded from the Gene Ontology (GO) category “DNA repair” (GO:0006281), including 356 human DNA repair genes. RNA sequencing data (Illumina HiSEq. 2000, Illumina) of 166 TCGA GBM samples was downloaded from the Broad Institute Firehose data standardization run on March 9, 2013. Partial correlation measures the degree of association between two variables, with influences from a third set of variables removed. To specify, the partial correlation between X and Y given a third set of variables Z is the correlation between the residuals obtained from the linear regression of X on Z and of Y on Z, respectively. We calculated the partial correlation between the expression of an Akt isoform and a DNA repair gene, with effects from the other Akt isoforms removed. The expression of 76 DNA repair genes were significantly associated with Akt3, but not with Akt1 or Akt2 (Benjamini–Hochberg adjusted false discovery rate < 0.05 and |partial correlation| >0.2).

Mutation Copy Number Variation Analysis.

The mutation data (Illumina Genome Analyzer DNA Sequencing, Illumina) of 291 TCGA GBM samples was downloaded from the Broad Institute Firehose data standardization run on March 9, 2013. Total number of mutations was calculated for each sample. The samples are then divided into two groups according to Akt3′s copy number. Specifically, the Akt3 low (high) copy number group consists of samples which are two MAD (Median Absolute Deviation) below (above) the median copy number value of Akt3. One-tailed t test is used to test the hypothesis that Akt3 high copy number group has lower mutation counts than the other group.

Statistical Analyses.

Differences in HGG and tumor proliferation index were analyzed with the one-sided Fisher’s exact test; H2AX foci and HR assay were analyzed via the one-sided t test with multiple testing correction. Please refer to SI Methods for detailed descriptions of bioinformatics analyses.

Animal Studies.

All animal experiments were performed in accordance with The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee guidelines.

Data Availability

Data deposition: The sequences reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE66177).

Acknowledgments

We thank Peter Vogt (The Scripps Research Institute) for discussions and for the RCAS-Akt plasmids. We also thank Bethany Alicie and Sarah Dunlap for technical assistance. This work was partially supported by NIH Grants CA141432, CA09850305, and U24CA143835; an MD Anderson Cancer Center core grant from the National Cancer Institute (CA16672); a grant from Goldhirsh Foundation; the Academy of Finland (Projects 132877); Sigrid Juselius Foundation; and the Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program (O.Y.-H. and M.N.). Y.S. was supported by an Odyssey Fellowship. K.J.G. was supported by a grant from the Academy of Finland (259038).

Supporting Information

Supporting Information (PDF)
Supporting Information
pnas.1414573112.sd01.xlsx
pnas.1414573112.sd02.xlsx
pnas.1414573112.sd03.xlsx

References

1
DA Altomare, JR Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455–7464 (2005).
2
E Gonzalez, TE McGraw, The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle 8, 2502–2508 (2009).
3
KH Khan, TA Yap, L Yan, D Cunningham, Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32, 253–265 (2013).
4
; Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
5
CW Brennan, et al., The somatic genomic landscape of glioblastoma. Cell; TCGA Research Network 155, 462–477 (2013).
6
H Wang, et al., Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84, 941–951 (2004).
7
GZ Cheng, et al., Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8, 2–6 (2008).
8
RL Dillon, WJ Muller, Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 70, 4260–4264 (2010).
9
IG Maroulakou, W Oemler, SP Naber, PN Tsichlis, Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67, 167–177 (2007).
10
YR Chin, A Toker, The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell 38, 333–344 (2010).
11
D Iliopoulos, et al., MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2, ra62 (2009).
12
P Villagrasa, et al., Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31, 4022–4033 (2012).
13
P Pu, C Kang, J Li, H Jiang, Antisense and dominant-negative AKT2 cDNA inhibits glioma cell invasion. Tumour Biol 25, 172–178 (2004).
14
P Pu, C Kang, J Li, H Jiang, J Cheng, The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. J Neurooncol 76, 1–11 (2006).
15
H Michiue, A Eguchi, M Scadeng, SF Dowdy, Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8, 2306–2313 (2009).
16
H Mure, et al., Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro-oncol 12, 221–232 (2010).
17
R Endersby, X Zhu, N Hay, DW Ellison, SJ Baker, Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res 71, 4106–4116 (2011).
18
M Cheung, A Sharma, SV Madhunapantula, GP Robertson, Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68, 3429–3439 (2008).
19
Y Shao, AE Aplin, Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70, 6670–6681 (2010).
20
G O’Hurley, et al., Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 64, 660–670 (2014).
21
K Nakatani, et al., Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274, 21528–21532 (1999).
22
S Banerji, et al., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409 (2012).
23
RM Easton, et al., Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25, 1869–1878 (2005).
24
KM Holmes, et al., Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci USA 109, 3475–3480 (2012).
25
SM Dunlap, et al., Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104, 11736–11741 (2007).
26
LM Moore, et al., IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 106, 16675–16679 (2009).
27
I Sanidas, et al., Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Mol Cell 53, 577–590 (2014).
28
SR Horman, et al., Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. Mol Cell 50, 356–367 (2013).
29
Q Jin, et al., Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3. Carcinogenesis 35, 2232–2243 (2014).
30
N Grabinski, et al., AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Cell Signal 26, 1021–1029 (2014).
31
DG Corum, PN Tsichlis, RC Muise-Helmericks, AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM-1. FASEB J 28, 395–407 (2014).
32
R Grantham, Amino acid difference formula to help explain protein evolution. Science 185, 862–864 (1974).
33
DS Ernst, et al., Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23, 569–575 (2005).
34
KG Chee, et al., The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5, 433–437 (2007).
35
TA Yap, et al., First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29, 4688–4695 (2011).
36
B Zhang, S Kirov, J Snoddy, WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33, W741–748 (2005).
37
Q Liu, KM Turner, WK Alfred Yung, K Chen, W Zhang, Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-oncol 16, 1313–1323 (2014).
38
Y Shiloh, Y Ziv, The ATM protein: The importance of being active. J Cell Biol 198, 273–275 (2012).
39
RO Mirimanoff, High-grade gliomas: Reality and hopes. Chin J Cancer 33, 1–3 (2014).
40
R Beroukhim, et al., Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104, 20007–20012 (2007).
41
GK Smyth, YH Yang, T Speed, Statistical issues in cDNA microarray data analysis. Methods Mol Biol 224, 111–136 (2003).
42
Y Benjamini, Y Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc, B 57, 289–300 (1995).

Information & Authors

Information

Published in

Go to Proceedings of the National Academy of Sciences
Go to Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences
Vol. 112 | No. 11
March 17, 2015
PubMed: 25737557

Classifications

Data Availability

Data deposition: The sequences reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE66177).

Submission history

Published online: March 3, 2015
Published in issue: March 17, 2015

Keywords

  1. Akt
  2. glioma
  3. DNA repair
  4. RCAS/tv-a mouse model

Acknowledgments

We thank Peter Vogt (The Scripps Research Institute) for discussions and for the RCAS-Akt plasmids. We also thank Bethany Alicie and Sarah Dunlap for technical assistance. This work was partially supported by NIH Grants CA141432, CA09850305, and U24CA143835; an MD Anderson Cancer Center core grant from the National Cancer Institute (CA16672); a grant from Goldhirsh Foundation; the Academy of Finland (Projects 132877); Sigrid Juselius Foundation; and the Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program (O.Y.-H. and M.N.). Y.S. was supported by an Odyssey Fellowship. K.J.G. was supported by a grant from the Academy of Finland (259038).

Notes

*This Direct Submission article had a prearranged editor.

Authors

Affiliations

Kristen M. Turner
Departments of aPathology and
Present address: Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093.
Youting Sun
Departments of aPathology and
Present address: Sequenom Laboratories, San Diego, CA 92121.
Ping Ji
Departments of aPathology and
Kirsi J. Granberg
Departments of aPathology and
Department of Signal Processing, Tampere University of Technology, Tampere, 33720, Finland; and
Brady Bernard
Department of Systems Biology, Institute for Systems Biology, Seattle, WA 98109
Limei Hu
Departments of aPathology and
David E. Cogdell
Departments of aPathology and
Xinhui Zhou
Departments of aPathology and
Olli Yli-Harja
Department of Signal Processing, Tampere University of Technology, Tampere, 33720, Finland; and
Matti Nykter
Department of Signal Processing, Tampere University of Technology, Tampere, 33720, Finland; and
Ilya Shmulevich
Department of Systems Biology, Institute for Systems Biology, Seattle, WA 98109
W. K. Alfred Yung
Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030;
Gregory N. Fuller
Departments of aPathology and
Departments of aPathology and

Notes

3
To whom correspondence should be addressed. Email: [email protected].
Author contributions: K.M.T., O.Y.-H., M.N., I.S., G.N.F., and W.Z. designed research; K.M.T., P.J., K.J.G., L.H., D.E.C., and X.Z. performed research; K.M.T., Y.S., K.J.G., B.B., O.Y.-H., M.N., I.S., W.K.A.Y., G.N.F., and W.Z. analyzed data; and K.M.T., W.K.A.Y., G.N.F., and W.Z. wrote the paper.

Competing Interests

The authors declare no conflict of interest.

Metrics & Citations

Metrics

Note: The article usage is presented with a three- to four-day delay and will update daily once available. Due to ths delay, usage data will not appear immediately following publication. Citation information is sourced from Crossref Cited-by service.


Citation statements




Altmetrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

Cited by

    Loading...

    View Options

    View options

    PDF format

    Download this article as a PDF file

    DOWNLOAD PDF

    Get Access

    Login options

    Check if you have access through your login credentials or your institution to get full access on this article.

    Personal login Institutional Login

    Recommend to a librarian

    Recommend PNAS to a Librarian

    Purchase options

    Purchase this article to get full access to it.

    Single Article Purchase

    Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression
    Proceedings of the National Academy of Sciences
    • Vol. 112
    • No. 11
    • pp. 3171-E1401

    Media

    Figures

    Tables

    Other

    Share

    Share

    Share article link

    Share on social media